Company intelligence / Profile preview

Indupro Soluciones

Seattle, Washington, United Statesindupro.com.co ↗

Ownership: Private
Development stage: Other

Overview

InduPro has raised $85 million in Series A funding to advance its first clinical product candidate targeting cancer tissue using proximity-based co-targeting. The company’s programs are currently preclinical with an IND filing anticipated in late 2025. No clinical results have been reported yet.

Therapeutic areas: OncologyImmunology
Modalities: Bispecific monoclonal antibodyAntibody-drug conjugateMonoclonal antibody
Industry: Biotech

Drug pipeline

1 asset

IDP-012

Preclinical

Partnerships

None publicly disclosed.

Beyond the preview

Go deeper on Indupro Soluciones.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Indupro Soluciones.

Explore the full profile